CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 1,000 enrolled
Drug / intervention
Polatuzumab Vedotin +7 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03274492
NCT03274492Phase 3Completed
CompareCT.gov

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Polatuzumab Vedotin in Combination With Rituximab and CHP (R-CHP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients With Diffuse Large B-Cell Lymphoma

Hoffmann-La Roche·interventional·Posted Sep 7, 2017·Updated May 8, 2026

In Brief

A Phase 3 clinical trial evaluating Polatuzumab Vedotin, Rituximab, and 6 other interventions for Diffuse Large B-Cell Lymphoma. Completed, enrolled 1,000 participants across 209 sites in 22 countries.

Detailed Summary

This Phase III, randomized, double-blind, placebo-controlled study will compare the efficacy, safety, and pharmacokinetics of polatuzumab vedotin plus R-CHP versus R-CHOP in participants with previously untreated diffuse large B-cell lymphoma (DLBCL).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiffuse Large B-Cell Lymphoma
CountriesAustralia, Austria, Belgium, Brazil, Canada, China, Czechia, France, Germany, Italy, Japan, New Zealand, Poland, Russia, South Korea, Spain, Switzerland, Taiwan, Turkey (Türkiye), Ukraine, United Kingdom, United States
Collaborators--

Timeline

Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedSep 7, 2017
Enrollment StartNov 16, 2017
Primary CompletionApr 30, 2026
TodayJul 2, 2026
Enrollment to primary: 8.5 yearsPosted 8.8 years ago

Interventions

Polatuzumab Vedotindrug

Polatuzumab vedotin IV infusion will be administered as per the schedule specified in the respective arm.

Rituximabdrug

Rituximab IV infusion will be administered as per the schedule specified in the respective arm.

Cyclophosphamidedrug

Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.

Doxorubicindrug

Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.

Vincristinedrug

Vincristine IV infusion will be administered as per the schedule specified in the respective arm.

Vincristine Placebodrug

Placebo matching to vincristine will be administered as per the schedule specified in the respective arm.

Prednisonedrug

Prednisone PO will be administered as per the schedule specified in the respective arm.

Polatuzumab vedotin Placebodrug

Placebo matching to polatuzumab vedotin will be administered as per the schedule specified in the respective arm.